Blog Band - Page 260 of 300

15

Feb 2022

PharmaShots Interview: 180 Life Sciences’ Dr. Jim Woody Shares Insight on Repurposing Anti-TNF to Meet Unmet Needs in Pain and Inflammation

In an interview with PharmaShots, Dr. Jim Woody, MD, Ph.D., Chief Executive Officer at 180 Life Sciences shared his insights on the Phase 2b study of anti-TNF for the treatment of the early Dupuytren's…

14

Feb 2022

EXCLUSIVE

Exclusive Interview with PharmaShots: John Meduri of Accelerate Diagnostics Shares Insight on Antimicrobial Resistance or AMR

In an interview with PharmaShots, John Meduri, Chief Strategy Officer at Accelerate Diagnostics shared his views on antimicrobial resistance and discuss the epidemiology of AMR cases in the US and…

10

Feb 2022

TOP 20

Top 20 Life Sciences Deals of 2021 by Total Deal Value

Shots: The life science industry saw high deal activity in 2021 staying in the range of an even busier 2020. Fourth-quarter 2021 set the tone with Recursion’s development and commercialization deal with Roche and Genentech…

09

Feb 2022

VIEWPOINTS

PharmaShots Interview: Myriad Genetics’ Todd Cohen Shares Insights on the Trends in Prostate Cancer and Precision Medicine

In an interview with PharmaShots, Todd Cohen, MD, Vice President of Medical Affairs/Medical Director of Urology at Myriad Genetics shares his views on the precision medicine and prognostic tests for Prostate Cancer Shots: The company reported the…

08

Feb 2022

VIEWPOINTS

PharmaShots Interview: Dermavant’s Philip M. Brown Shares Insights on the Clinical Data of Tapinarof Published in NEJM

In an interview with PharmaShots, Philip M. Brown, MD, JD, Chief Medical Officer at Dermavant shares his views on the P-III (PSOARING 1 & 2) trials of tapinarof for the treatment of Plaque Psoriasis Shots: The P-III…

07

Feb 2022

EXCLUSIVE

Exclusive Interview with PharmaShots: Moshe Safran of RSIP Vision Share Insight on the 3D Reconstruction Technology

In an interview with PharmaShots, Moshe Safran, CEO at RSIP Vision shared his views on the new coronary module in the complete 3D reconstruction of the coronary vasculature during angiography Shots: The company reported the 3D…

03

Feb 2022

INSIGHTS+

Insights+ Key Biosimilars Events of January 2022

Insights+ Key Biosimilars Events of January 2022 Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Biosimilars are expected to be…

02

Feb 2022

VIEWPOINTS

PharmaShots Interview: Accenture Life Sciences’ Laura Dix Shares Insights on the New Rules of Engagement to Provide HCPs New Interactions

In an interview with PharmaShots, Laura Dix, a Managing Director in Accenture’s Life Sciences Strategy and Consulting practice shares her views on the new research & provides more useful, data-driven information to HCPs Shots: The…

31

Jan 2022

VIEWPOINTS

PharmaShots Interview: Nanobiotix’s Laurent Levy Shares Insights on the P-III (NANORAY-312) Study of NBTXR3 for the Treatment of Head and Neck Squamous Cell Carcinoma

In an interview with PharmaShots, Laurent Levy, Co-Founder & CEO at Nanobiotix shares his views on the first patient enrollment of NBTXR3 in P-III (NANORAY-312) study for the treatment of head and neck squamous cell carcinoma…

27

Jan 2022

INSIGHTS+

Insights+: The US FDA New Drug Approvals in December 2021

The US FDA has approved 8 NDAs and 1 BLAs in Dec 2021, leading to treatments for patients and advances in the health care industry. The CDER and CBER approved…

PharmaShots Interview: 180 Life Sciences’ Dr. Jim Woody Shares Insight on Repurposing Anti-TNF to Meet Unmet Needs in Pain and Inflammation

Exclusive Interview with PharmaShots: John Meduri of Accelerate Diagnostics Shares Insight on Antimicrobial Resistance or AMR

Top 20 Life Sciences Deals of 2021 by Total Deal Value

PharmaShots Interview: Myriad Genetics’ Todd Cohen Shares Insights on the Trends in Prostate Cancer and Precision Medicine

PharmaShots Interview: Dermavant’s Philip M. Brown Shares Insights on the Clinical Data of Tapinarof Published in NEJM

Exclusive Interview with PharmaShots: Moshe Safran of RSIP Vision Share Insight on the 3D Reconstruction Technology

Insights+ Key Biosimilars Events of January 2022

PharmaShots Interview: Accenture Life Sciences’ Laura Dix Shares Insights on the New Rules of Engagement to Provide HCPs New Interactions

PharmaShots Interview: Nanobiotix’s Laurent Levy Shares Insights on the P-III (NANORAY-312) Study of NBTXR3 for the Treatment of Head and Neck Squamous Cell Carcinoma

Insights+: The US FDA New Drug Approvals in December 2021

Contact US

OUR INFORMATION

FOLLOW US